Global pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Thursday that it has received approval from the US Food and Drug Administration for Inluriyo (imlunestrant, 200 mg tablets).
The product is an oral estrogen receptor antagonist, intended for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET).
During the Phase 3 EMBER-3 trial, Inluriyo decreased the risk of progression or death by 38% compared to ET. Among patients with ESR1-mutated MBC, the drug significantly improved progression-free survival (PFS) compared to fulvestrant or exemestane.
Inluriyo was approved by the FDA based on the outcome of the EMBER-3 trial. It is expected to be available in the United States in the coming weeks.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval